# GHK-Cu: Research Overview — Peptides Emporium > A literature summary of GHK-Cu (copper tripeptide-1), studied for skin regeneration, collagen and matrix synthesis. Covers fibroblast signaling, gene expression data, hair growth evidence and delivery limits. A tiny copper-binding tripeptide that signals fibroblasts to rebuild skin scaffolding — with real human topical evidence and a delivery problem baked into its chemistry. ## The short version GHK-Cu is a very small peptide — three amino acids (glycine, histidine, lysine) bound to a single copper ion. You will also see it called copper tripeptide-1. The same GHK sequence occurs naturally inside type I collagen, the main structural protein of skin and tendon, which gives away what it does: it signals the cells that build skin's scaffolding — dermal fibroblasts — to make more collagen, elastin and the other matrix components that keep skin firm and repair-ready [11]. Of the two peptides on this desk, GHK-Cu has the most human evidence. But that evidence is mostly *topical* — applied in creams and serums to the skin surface — and it comes with a built-in complication: GHK-Cu does not cross intact skin well on its own [8]. Topical copper-peptide cosmetics are legal and widely sold with a long safety record. Injectable or systemic use is unapproved and research-only. This page summarizes what the studies show; no dose or regimen is recommended. ## What it is GHK-Cu is a linear tripeptide — glycyl-L-histidyl-L-lysine — chelated one-to-one with a copper(II) ion. Chelation means the copper is held in a stable, claw-like grip by the histidine imidazole ring, the glycine amino group, and a backbone nitrogen, with the lysine side chain left free. It carries a small positive charge. Molecular formula C14H23CuN6O4+. The bare GHK sequence appears endogenously within the alpha-2(I) chain of type I collagen and in the matrix protein SPARC/osteonectin, so the body already uses this motif. Copper coordination is required for most reported bioactivities: without the ion, the peptide's collagen-cross-linking and antioxidant actions are diminished [11]. GHK and GHK-Cu are frequently conflated in secondary sources; the form used in a given study genuinely matters. GHK-Cu has no approved therapeutic indication. Topical copper tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK. Systemic or injectable formulations are unapproved research chemicals with no established regulatory pathway. ## How it works GHK-Cu acts as both a *copper chaperone* and a pleiotropic signaling molecule. At picomolar-to-nanomolar concentrations — extremely low — it directly tells dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and decorin (a proteoglycan that regulates collagen fibril diameter) while rebalancing the matrix metalloproteinase enzymes that break matrix down against their natural inhibitors (TIMPs) [11]. The copper ion itself enables lysyl oxidase-mediated cross-linking that knits collagen and elastin fibers together, plus a superoxide-dismutase-like antioxidant action. Its effects reach the gene level. A Connectivity Map analysis reported that GHK shifts expression of roughly 31.2% of human genes at a 50%-or-greater change threshold — about 59% of affected genes up, 41% down — with strong stimulation of the ubiquitin-proteasome protein-quality-control system and DNA-repair and antioxidant gene sets [9]. One honest correction belongs here: the widely repeated "approximately 4,000 genes" figure is an extrapolation; the verified 50%-threshold table reports on the order of 2,100 genes [9]. At the skin surface, the mechanism faces a practical obstacle. GHK's octanol-water partition coefficient (clogP) is -2.24 — strongly negative, meaning it resists crossing lipid barriers. Intact skin stops most of it. Delivery strategies such as palmitoylation (adding a fatty-acid chain to improve membrane crossing) and microneedle pretreatment have been studied as ways around this [8]. ## What the research shows *Skin regeneration (canonical review).* The field's foundational synthesis documents GHK-Cu stimulating synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin. It notes that plasma GHK falls from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 — a natural decline that has been proposed as one factor in age-related matrix degradation. In controlled clinical comparisons, topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid, with documented placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density [11]. *Gene expression (2018).* A Connectivity Map analysis quantified GHK's transcriptomic shift toward tissue-repair, protein-quality-control, DNA-fidelity and antioxidant programs, reporting the 31.2% figure at the 50%-threshold [9]. *Hair growth (controlled human trial).* In a 6-month randomized trial of 45 men with androgenetic alopecia (Norwood-Hamilton grades II-V), a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL versus 9.6 for placebo (p<0.05), with no adverse events in any group [10]. This is the strongest controlled human efficacy signal for a GHK-containing topical; it used a combination product, not pure GHK-Cu. *Delivery problem (2025 review).* A current review confirms poor stratum-corneum permeability as the central challenge, reports the procollagen 70% comparison again, and evaluates fixes: palmitoylation raises clogP from -2.24 to 1.14, and microneedle pretreatment allows approximately 134 nmol GHK to permeate versus none through intact skin [8]. *Skin penetration quantified.* An ex vivo study measured copper delivery from GHK-Cu through dermatomed human skin: over 48 hours, 136.2 micrograms/cm² permeated and 97 micrograms/cm² was retained as a dermal depot, confirming that topical application does reach the dermis at measurable concentrations [12]. ## Reported effects, cautions & safety Topical copper-peptide products carry a long real-world safety record. The cautions below are from the research literature, not from user reports (no community-sourced signals were compiled for GHK-Cu in this desk's source material). - *No approved drug indication.* No FDA- or EMA-approved therapeutic GHK-Cu product exists for any route. Topical copper tripeptide-1 is a legal cosmetic; injectable or systemic use is unapproved [8]. - *Limited human evidence beyond topical skin studies.* Human data are confined to small topical dermatology trials and one 45-patient combination hair-loss study. No validated pharmacokinetic data for injectable or systemic GHK-Cu exist; community dosing protocols have no peer-reviewed basis [10]. - *Pigmentation risk with some formulations.* Localized hyperpigmentation has been reported with some topical copper-peptide applications — in one acne-scar microneedling study, around 40% of subjects were affected. The copper's role in melanin synthesis is the plausible mechanism. - *Formulation incompatibility.* Vitamin C (ascorbic acid) and low-pH acids can destroy both actives through copper interactions — a practical formulation and user-error risk. - *Theoretical copper accumulation.* Prolonged systemic use raises a theoretical copper-balance concern, though no human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record. - *Single-investigator concentration.* A large share of foundational GHK-Cu mechanistic and review literature originates from one investigator and colleagues, limiting independent replication of the broader gene-expression and anti-aging claims [9]. ## Where it fits in skin research GHK-Cu is the matrix specialist on this desk — approaching skin from the connective tissue upward rather than from the pigmentation pathway. Where [Melanotan II](/melanotan-2) produces an acute receptor-mediated signal that can tan skin within days, GHK-Cu operates slowly at the scaffolding level, supporting the collagen and elastin that determine skin's structure and resilience. It also has the most defensible human evidence of the two, though that evidence is largely topical and small-scale. The delivery problem is its defining limitation: until the peptide is inside the skin, the signaling cannot start, and crossing the stratum corneum is genuinely hard without formulation engineering. See the [comparison page](/compare) for how it lines up against Melanotan II across the key dimensions. ![GHK-Cu copper tripeptide and collagen lattice research illustration](/images/ghk-cu.webp) --- Peer-reviewed literature on two skin peptides. Not a clinic, not a vendor, not a dose.